TY - CHAP
T1 - Pakistan: Z Pharma’s journey from vision to reality
AU - Mubarik, Shujaat
AU - Butt, Rehan Muzammil
PY - 2026/6
Y1 - 2026/6
N2 - Z Pharma, founded by Dr. AR, is a pharmaceutical company specializing in treatments for neurodegenerative diseases, particularly Alzheimer’s. Driven by personal experiences and academic expertise, Dr. AR leveraged AI to revolutionize drug discovery, aiming to personalize treatments and improve efficacy. Despite initial funding challenges, her refined pitches secured seed funding from angel investors, enabling the establishment of state-of-the-art labs and a skilled team. The company faced operational hurdles, including supply chain inefficiencies and cultural differences within its diverse workforce. Innovative solutions, such as interactive AI demonstrations for regulatory bodies like the FDA, helped overcome regulatory barriers. Z Pharma’s growth was marked by securing venture capital, a successful IPO, and scaling production while navigating international regulations. During the COVID-19 pandemic, Z Pharma pivoted to produce PPE and ventilators, showcasing adaptability. The pandemic disrupted clinical trials and supply chains, but the company responded with virtual trials and diversified sourcing. Digitalization played a key role, with AI-driven research and ERP systems enhancing efficiency. Z Pharma’s commitment to sustainability is evident in green manufacturing, ethical labour practices, and community health initiatives, such as combating childhood blindness in Karachi. The company’s journey highlights the synergy of strategic planning, innovation, and ethical practices, positioning it as a leader in the pharmaceutical industry. Key lessons include the importance of diverse funding, cultural integration, and agility in responding to global challenges.
AB - Z Pharma, founded by Dr. AR, is a pharmaceutical company specializing in treatments for neurodegenerative diseases, particularly Alzheimer’s. Driven by personal experiences and academic expertise, Dr. AR leveraged AI to revolutionize drug discovery, aiming to personalize treatments and improve efficacy. Despite initial funding challenges, her refined pitches secured seed funding from angel investors, enabling the establishment of state-of-the-art labs and a skilled team. The company faced operational hurdles, including supply chain inefficiencies and cultural differences within its diverse workforce. Innovative solutions, such as interactive AI demonstrations for regulatory bodies like the FDA, helped overcome regulatory barriers. Z Pharma’s growth was marked by securing venture capital, a successful IPO, and scaling production while navigating international regulations. During the COVID-19 pandemic, Z Pharma pivoted to produce PPE and ventilators, showcasing adaptability. The pandemic disrupted clinical trials and supply chains, but the company responded with virtual trials and diversified sourcing. Digitalization played a key role, with AI-driven research and ERP systems enhancing efficiency. Z Pharma’s commitment to sustainability is evident in green manufacturing, ethical labour practices, and community health initiatives, such as combating childhood blindness in Karachi. The company’s journey highlights the synergy of strategic planning, innovation, and ethical practices, positioning it as a leader in the pharmaceutical industry. Key lessons include the importance of diverse funding, cultural integration, and agility in responding to global challenges.
M3 - Chapter (peer-reviewed)
SN - 9781035328383
T3 - Elgar Cases in Entreprenuership
SP - 96
EP - 117
BT - Cases on Entrepreneurship in the Asia-Pacific
A2 - Baskaran, Angathevar
A2 - Govindaraju, VGR CHandran
A2 - Selvarajan, Sonia Kumari
PB - Edward Elgar Publishing
ER -